FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Denise Yardley

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Mythili Shastry; Denise A Yardley
Updates in the treatment of basal/triple-negative breast cancer.
Denise A Yardley
Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions.
Denise A Yardley; Paul Richards; Mansoor N Salleh; David M Waterhouse; Linda Bosserman; Michelle L DeSilvio; Maura K Hagan; Lowell Hart; Janine M Mahoney; Yasir Nagarwala
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Denise Yardley (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mythili Shastry; Denise A Yardley
Updates in the treatment of basal/triple-negative breast cancer.
Current opinion in obstetrics & gynecology 2013;25(1):40-8.
2013: Denise A Yardley
Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions.
Breast cancer : basic and clinical research 2013;7():7-22.
2013: Denise A Yardley; Paul Richards; Mansoor N Salleh; David M Waterhouse; Linda Bosserman; Michelle L DeSilvio; Maura K Hagan; Lowell Hart; Janine M Mahoney; Yasir Nagarwala
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Breast cancer research and treatment 2013;137(2):457-64.
2012: Rachel Borson; Jane Bromund; Steven Hager; Graydon Harker; Grant Harrer; William Horvath; Michael Jones; Lori J Kornberg; Fred J Kudrik; Stephen C Malamud; Coleman Obasaju; Mauro Orlando; James Reeves; Datchen Fritz Tai; Guy Tillinghast; Edward Arrowsmith; Thaddeus Beck; Haoyue Zeigler; Denise A Yardley
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Clinical breast cancer 2012;12(5):322-30.
2012: Suzanne F Jones; Adil Mohyuddin; Dana S Thompson; Denise A Yardley; Johanna C Bendell; Jeffrey R Infante; Howard A Burris
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;70(3):471-5.
2011: Suzanne F Jones; David R Spigel; Dana F Thompson; Denise A Yardley; Howard A Burris
A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
Clinical advances in hematology & oncology : H&O 2011;9(11):845-52.
2011: Denise A Yardley; Howard A Burris; Raul Castillo; Anup Lahiry; Richard Locicero; Eric Raefsky; Mythili Shastry; Dana Thompson; John D Hainsworth
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Clinical breast cancer 2011;11(5):297-305.
2011: Denise A Yardley; Mark Rubin; Dianna L Shipley; Edward Arrowsmith; John Barton; Howard A Burris; Bobby L Clark; John D Hainsworth
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Clinical breast cancer 2011;11(3):146-52.
2011: David R Spigel; John D Hainsworth; Howard A Burris; David C Molthrop; Nancy Peacock; Michael Kommor; Elizabeth R Vazquez; F Anthony Greco; Denise A Yardley
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
Clinical advances in hematology & oncology : H&O 2011;9(4):280-6.
2011: Suzanne F Jones; Johanna C Bendell; Jeffrey R Infante; David R Spigel; Dana S Thompson; Denise A Yardley; F Anthony Greco; Patrick B Murphy; Howard A Burris
A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.
Clinical advances in hematology & oncology : H&O 2011;9(3):225-30.
2011: Jeffrey R Infante; Suzanne F Jones; Johanna C Bendell; David R Spigel; Denise A Yardley; Colin D Weekes; Wells A Messersmith; John D Hainsworth; Howard A Burris
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
European journal of cancer (Oxford, England : 1990) 2011;47(2):199-205.
2010: Denise A Yardley; Michael McCleod; Fred Schreiber; Patrick Murphy; Jeffrey Patton; Dana S Thompson; Mythili Shastry; Mark Rubin; Marianne Melnik; Howard A Burris; John D Hainsworth
A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer.
Cancer investigation 2010;28(9):925-31.
2010: Denise A Yardley; Davey Daniel; Michael Stipanov; D Randolph Drosick; Mark Mainwaring; James Peyton; Mythili Shastry; John D Hainsworth
A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
Cancer investigation 2010;28(8):865-71.
2010: Denise A Yardley; John Zubkus; Brooke Daniel; Roger Inhorn; Cassie M Lane; Elizabeth R Vazquez; Yuval Naot; Howard A Burris; John D Hainsworth
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
Clinical breast cancer 2010;10(5):367-72.
2010: Denise A Yardley; Nancy W Peacock; Natalie R Dickson; Melissa B White; Elizabeth R Vázquez; John T Foust; Richard Grapski; Linda K Hendricks; William L Scott; John D Hainsworth
A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Clinical breast cancer 2010;10(3):217-23.
2010: Howard A Burris; Suzanne F Jones; Dianna Shipley; Anthony A Meluch; F Anthony Greco; John H Barton; Denise A Yardley; John D Hainsworth
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Cancer investigation 2010;28(4):408-12.
2010: Denise A Yardley
Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety.
Clinical breast cancer 2010;10(2):119-29.
2010: Denise A Yardley
Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents.
Clinical breast cancer 2010;10(1):64-73.
2010: David R Spigel; John D Hainsworth; Denise A Yardley; Eric Raefsky; Jeffrey Patton; Nancy Peacock; Cindy Farley; Howard A Burris; F Anthony Greco
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(1):43-8.
2009: David R Spigel; F Anthony Greco; John D Zubkus; Patrick B Murphy; Ruben A Saez; Cindy Farley; Denise A Yardley; Howard A Burris; John D Hainsworth
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(12):1555-60.
2009: Denise A Yardley; Howard A Burris; David R Spigel; Bobby L Clark; Elizabeth Vazquez; Dianna L Shipley; John Barton; Dana Thompson; Ignacio Montes; F Anthony Greco; John D Hainsworth
A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer.
Clinical breast cancer 2009;9(4):247-52.
2009: Denise A Yardley; Howard A Burris; Tiffanie M Markus; David R Spigel; F Anthony Greco; Mark Mainwaring; David M Waterhouse; Charles D Webb; John D Hainsworth
Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
Clinical breast cancer 2009;9(4):237-42.
2009: Denise A Yardley; Howard A Burris; Sarah Hanson; F Anthony Greco; David R Spigel; John Barton; John D Hainsworth
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
Clinical breast cancer 2009;9(3):178-83.
2009: Jeffrey R Infante; Denise A Yardley; Howard A Burris; F Anthony Greco; Cindy P Farley; Charles Webb; David R Spigel; John D Hainsworth
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Clinical breast cancer 2009;9(1):23-8.
2008: Denise A Yardley; Howard A Burris; Lisa Simons; David R Spigel; F Anthony Greco; John H Barton; Dianna L Shipley; David Drosick; John D Hainsworth
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
Clinical breast cancer 2008;8(5):425-31.
2008: Denise A Yardley; Howard A Burris; Cindy P Farley; John H Barton; Nancy W Peacock; David R Spigel; F Anthony Greco; John D Hainsworth
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
Clinical breast cancer 2008;8(3):242-8.
2007: F Anthony Greco; David R Spigel; Michel E Kuzur; Dianna L Shipley; James R Gray; Dana S Thompson; Howard A Burris; Denise A Yardley; Asim Pati; Charles D Webb; Jitendra G Gandhi; John D Hainsworth
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
Clinical lung cancer 2007;8(8):483-7.
2007: David R Spigel; John D Hainsworth; Lisa Simons; Christina Meng; Howard A Burris; Denise A Yardley; Richard Grapski; Marshall Schreeder; Padmaja V Mallidi; F Anthony Greco
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(9):854-61.
2006: John D Hainsworth; Denise A Yardley; David R Spigel; Anthony A Meluch; David A Rinaldi; Frederick M Schnell; F Anthony Greco
Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial.
Cancer investigation 2006;24(5):469-73.
2005: David R Spigel; John D Hainsworth; Emily R Burkett; Howard A Burris; Denise A Yardley; Melodie Thomas; Suzanne F Jones; Natalie R Dickson; Daniel C Scullin; James E Bradof; James R Rubinsak; Joseph E Brierre; F Anthony Greco
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Clinical lung cancer 2005;7(2):127-32.
2004: Denise A Yardley
Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
Seminars in oncology 2004;31(2 Suppl 5):37-44.
2004: F Anthony Greco; Gladys I Rodriguez; Don W Shaffer; Robert Hermann; Sharlene Litchy; Denise A Yardley; Howard A Burris; Lisa H Morrissey; Joan B Erland; John D Hainsworth
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
The oncologist 2004;9(6):644-52.
2004: Denise A Yardley
Gemcitabine and taxanes as a new standard of care in breast cancer.
Clinical breast cancer 2004;4 Suppl 3():S107-12.
2003: Suzanne F Jones; Howard A Burris; John D Hainsworth; Denise A Yardley; Eric A Raefsky; Fernando T Miranda; Michel E Kuzur; Noel T Willcutt; Melissa B White; F Anthony Greco
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Oncology (Williston Park, N.Y.) 2003;17(5 Suppl 5):36-40.
2002: John D Hainsworth; Sharlene Litchy; Howard A Burris; Daniel C Scullin; Stephen Corso; Denise A Yardley; Lisa H Morrissey; F Anthony Greco
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(20):4261-7.
2002: John D Hainsworth; Anthony A Meluch; Suzanne McClurkan; James R Gray; Steven L Stroup; Howard A Burris; Denise A Yardley; James E Bradof; Kathleen Yost; James K Ellis; F Anthony Greco
Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Cancer journal (Sudbury, Mass.) 2002;8(4):311-21.
2001: John D Hainsworth; Howard A Burris; Denise A Yardley; James E Bradof; Manuel Grimaldi; Leonard A Kalman; T Sullivan; Margaret Baker; Joan B Erland; F Anthony Greco
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(15):3500-5.